The biotechnology company uses a holding company model to develop protein-based technologies that deplete pathogenic cells and agents in various diseases, including hematologic neoplasms, solid cancers, auto-immune disorders, and diseases of protein aggregation. With a portfolio of attractive projects, Dren Bio aims to create value with multiple stand-alone assets, providing healthcare professionals with innovative solutions to tackle deadly diseases.